Safe Intelligence
United Kingdom
- London
- 21/02/2025
- Seed
- $5,253,443
Safe Intelligence is a venture backed spin-out from Imperial College London, developing software to make AI safe and secure. Our overarching ambition is to help realise a society where people seamlessly interact with trustworthy AI.
- Industry Software Development
- Website https://safeintelligence.ai/
- LinkedIn https://www.linkedin.com/company/safe-intelligence/
Related People
Steven WillmottFounder
United Kingdom -
London, England
Steven Willmott is a company founder and technologies with deep interest in AI and the evolution of an open Internet. He's currently leading product and engineering at Safe Intelligence and is a Venture Partner at Piton Capital. He has a 100+ scientific publications and holds a Doctorate in AI from EPFL in Switzerland.
Prior to Safe Intelligence and Piton, Steve was the Co-Founder and CEO of Timewarp Labs and 3scale Inc. Red Hat acquired 3scale and he continued as a Senior Director and Head of API Infrastructure. He has also been a key contributor to community efforts such as the APIStrat conference series, Open API Initiative, APICommons and APIS.json. He's actively involved in APIS.IO.
Before 3scale, he was a senior researcher in distributed systems, Artificial Intelligence, Web Services, and Semantic Web technology. Co-authoring more than 100 publications, Steve has coordinated major international R&D projects under European Commission's Framework international and national projects. Steven also participated as an evaluator and reviewer in European Commission R&D programs and has done so for the EPSRC (UK) and NASA Intelligent Systems programs (USA).
Current Angel investments include: Elemeno Health, GDPR.Dev, Restack.IO, Sharplaunch, SafeIntelligence, Mercury. LP investment in Flori Ventures.
Publications are available at Google Scholar: http://t.co/o51esCjC.
Regular AI centric blog posts can be found at http://steampunkai.com.
Canopy(1) | $22,000,000 | (Jan 13, 2026)
Onsetto | $2,200,000 | (Jan 13, 2026)
BlueNalu | $11,000,000 | (Jan 13, 2026)
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
Kinaset Therapeutics | $103,000,000 | (Jan 13, 2026)
Diagonal Therapeutics | $125,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)
encoord | $2,000,000 | (Jan 13, 2026)
Vibrant Therapeutics | $61,000,000 | (Jan 13, 2026)
Avenue Biosciences | $7,500,000 | (Jan 13, 2026)
Unusual | $3,600,000 | (Jan 13, 2026)